Skip to main content
Premium Trial:

Request an Annual Quote

The Mechanism of Metformin


The diabetes drug metformin has long been thought to have anti-cancer effects, and researchers have been busy studying it. Now, according to a press release from the American Association for Cancer Research, new preclinical trials have shown that metformin may work in part by destroying cancer stem cells. Researchers at the Spanish National Cancer Research Centre, who conducted the research, also say that when they combined metformin with standard pancreatic cancer chemotherapy in mice implanted with a set of patient-derived tumors, the combination of drugs destroyed all cancer stem cells and more differentiated cancer cells than chemotherapy alone.

Over the past several years, AACR says, pancreatic cancer treatments have been thought to be inadequate because they didn't address the problem of stem cells, which are generally resistant to therapy. "The researchers found that metformin pretreated cancer stem cells were particularly sensitive to alterations to their metabolism through the activation of AMPK," AACR says. Targeting these cells, the researchers say, may help raise survival rates. They add that disease relapse was also prevented with the addition of metformin.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.